Sava Technologies is developing wearable glucose microsensors that continuously measure glucose beneath the skin through a minimally invasive approach. Unlike conventional continuous glucose monitors, the technology aims to provide a more comfortable monitoring experience while offering additional health insights. Its underlying platform could eventually track other biomarkers beyond glucose.
The device is being developed for non-adjunctive use, allowing insulin dosing decisions without routine confirmation through separate blood glucose measurements. Sava plans to conduct a pivotal clinical study in 2026 and is targeting European regulatory approval and commercialization within 18 to 24 months.
Through its partnership with Ascensia Diabetes Care, Sava gains access to established distribution capabilities and diabetes management expertise. Ascensia will initially handle European commercialization, with plans to use retail and reimbursement channels. The agreement could help bring specialized monitoring technology to more patients while expanding Ascensia's diabetes care portfolio.
Image Credit: Ascensia
What Makes This Trend Stand Out
- Minimally Invasive Biosensing
- Microsensor formats are reshaping continuous monitoring by reducing discomfort while preserving clinically useful real-time data streams.
- Multi-biomarker Wearables
- Platforms built beyond single-condition tracking create room for broader metabolic, hormonal, and wellness intelligence in everyday devices.
- Non-adjunctive Diabetes Monitoring
- Regulator-ready sensors that support insulin dosing decisions without confirmatory fingersticks signal a shift toward greater treatment autonomy.
Sectors Adopting This
- Diabetes Care
- More comfortable continuous glucose systems expand competitive possibilities for device makers, care providers, and therapy management platforms.
- Medical Devices
- Miniaturized implant-adjacent sensors highlight new product categories at the intersection of wearables, diagnostics, and regulated clinical hardware.
- Digital Health
- Connected glucose and biomarker data enables integrated services spanning remote monitoring, personalized coaching, reimbursement workflows, and clinical decision support.
